Review
Oncology
Xinyu Cheng, Huilan Wang, Zhongyu Wang, Bo Zhu, Haixia Long
Summary: Tumor-associated myeloid cells (TAMCs) are crucial immune cell populations in the tumor microenvironment and have a significant impact on immune checkpoint blockade efficacy. Understanding the origin of TAMCs is essential for determining their functional diversity and developing cancer immunotherapy strategies. This review article provides an overview of recent research progress on evaluating the heterogeneity of TAMC origins. It also summarizes major therapeutic strategies targeting TAMCs with diverse sources, shedding light on their implications for cancer immunotherapies.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Veronica Huber, Lorenza Di Guardo, Luca Lalli, Daniele Giardiello, Agata Cova, Paola Squarcina, Paola Frati, Anna Maria Di Giacomo, Lorenzo Pilla, Marcella Tazzari, Chiara Camisaschi, Flavio Arienti, Chiara Castelli, Monica Rodolfo, Valeria Beretta, Massimo Di Nicola, Michele Maio, Michele Del Vecchio, Filippo de Braud, Luigi Mariani, Licia Rivoltini
Summary: A multistep downsizing process identified a myeloid index score (MIS) composed of four cell subsets that stratified melanoma patients based on prognosis. The MIS serves as a simple blood biomarker in real-life oncology, aiding in tailoring therapeutic choices.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Pei-Yu Chen, Wen-Fei Wei, Hong-Zhen Wu, Liang-Sheng Fan, Wei Wang
Summary: CAFs are important and heterogeneous components of the tumor extracellular matrix, with different origins and biomarkers, playing a role in immune regulation of the tumor microenvironment and exerting immunosuppressive functions through various mechanisms. Inhibition of CAFs and targeted therapy against CAFs offer new adjuvant means for immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Lu Chen, Yuchen Wang, Qingqing Hu, Yuxi Liu, Xuchen Qi, Zhihua Tang, Haihong Hu, Nengming Lin, Su Zeng, Lushan Yu
Summary: The tumor microenvironment (TME) plays a crucial role in tumor progression by impeding the immune response through altering the metabolic activity of immune cells. Transporter-mediated regulation of nutrient acquisition and metabolite efflux is important for the proliferation and physiological functions of both tumor and immune cells, as well as for modulating immune responses in the TME. This review summarizes the metabolic characteristics of the TME, discusses the effects of abundant metabolites on immune cell function and transporter expression, and examines the mechanism of tumor immune escape caused by transporter dysfunction. Additionally, transporter-targeted antitumor therapeutic strategies are introduced to provide new insights into the development of antitumor drugs and rational drug usage for clinical cancer therapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Tsuyoshi Kadomatsu, Chiaki Hara, Ryoma Kurahashi, Haruki Horiguchi, Jun Morinaga, Keishi Miyata, Sohtaro Kurano, Hisashi Kanemaru, Satoshi Fukushima, Kimi Araki, Masaya Baba, W. Marston Linehan, Tomomi Kamba, Yuichi Oike
Summary: Deficiency of ANGPTL2 in renal tubular epithelial cells slows tumor progression in the tRCC mouse model and promotes infiltration of activated CD8(+) T-cells in kidney tissues. Moreover, Angptl2-deficient tumor cells show enhanced interferon gamma-induced expression of MHC-I and increased susceptibility to CD8(+) T-cell-mediated anti-tumor immune responses.
MOLECULAR ONCOLOGY
(2023)
Review
Immunology
Alberto Mantovani, Federica Marchesi, Sebastien Jaillon, Cecilia Garlanda, Paola Allavena
Summary: Myeloid cells in tumor tissues, including tumor-associated macrophages and tumor-associated neutrophils, play crucial roles in tumor growth and invasion. In recent years, successful therapeutic approaches have been developed and tested in preclinical cancer models, with some strategies reaching clinical trials.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Oncology
Feifei Guo, Yi Zhang, Ling Bai, Jiuwei Cui
Summary: Cancer stem cells (CSCs) are a small group of cancer cells with stem cell-like properties, which can be used for identifying malignant tumor phenotypes and patients with poor prognosis. Targeting CSCs has been shown to improve the effectiveness of cancer therapies. However, CSCs are resistant to conventional treatment methods such as radiotherapy and chemotherapy, hence the need for more effective anti-CSC therapies.
Article
Immunology
Takaaki Tatsuguchi, Takehito Uruno, Yuki Sugiura, Daiji Sakata, Yoshihiro Izumi, Tetsuya Sakurai, Yuko Hattori, Eiji Oki, Naoto Kubota, Koshiro Nishimoto, Masafumi Oyama, Kazufumi Kunimura, Takuto Ohki, Takeshi Bamba, Hideaki Tahara, Michiie Sakamoto, Masafumi Nakamura, Makoto Suematsu, Yoshinori Fukui
Summary: Effective tumor immunotherapy requires physical contact between T cells and cancer cells. However, cancer cells can produce a cholesterol sulfate that inhibits DOCK2, preventing infiltration of effector T cells.
INTERNATIONAL IMMUNOLOGY
(2022)
Review
Oncology
Maximilian Haist, Henner Stege, Stephan Grabbe, Matthias Bros
Summary: Immunotherapy has shown benefits for advanced cancer patients, but many still do not respond to treatment. The accumulation of immunosuppressive cell populations like MDSC and Treg in the tumor microenvironment contributes to immune resistance and limits the effectiveness of immunotherapy.
Review
Cell Biology
Martina Mang Leng Lei, Terence Kin Wah Lee
Summary: Immune cells play a crucial role in driving cancer cells towards stemness and enabling cancer stem cells to evade immune surveillance by affecting various immune cells in the tumor microenvironment. Targeting CSCs with immunotherapy disrupts the interaction between immune cells and CSCs, offering a novel strategy against cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Yu Chen, Yanquan Xu, Huakan Zhao, Yu Zhou, Jiangang Zhang, Juan Lei, Lei Wu, Mingyue Zhou, Jingchun Wang, Shuai Yang, Xiao Zhang, Guifang Yan, Yongsheng Li
Summary: Cancer immunotherapy targeting myeloid-derived suppressor cells (MDSCs) is a promising anti-cancer strategy. This study explored the regulatory mechanisms of cholesterol metabolic reprogramming in MDSCs and found that cholesterol deficiency increased the immunosuppressive activity of MDSCs. Mechanistically, cholesterol elimination induced nuclear accumulation of LXR beta and enhanced the binding of LXR beta-RXR alpha on Arg1 promoter. Furthermore, itraconazole improved MDSC immunosuppressive activity and promoted tumor growth by inhibiting the RIPK3-AKT-mTORC1 pathway and impeding cholesterol synthesis.
Article
Oncology
Nan Xiao, Xiaodong Zhu, Kangshuai Li, Yifan Chen, Xuefeng Liu, Bin Xu, Ming Lei, Jiejie Xu, Hui-Chuan Sun
Summary: This study found that Siglec-10(hi) TAMs in HCC patients are associated with immune suppression and poor prognosis. Blocking Siglec-10 can enhance the anti-tumor effects of CD8(+) T cells and improve the efficacy of PD-1 inhibitors.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Hiroshi Imazeki, Yamato Ogiwara, Mami Kawamura, Narikazu Boku, Chie Kudo-Saito
Summary: The study found that CD11b(+)CTLA4(+) cells in metastatic CRC patients promote tumor progression and metastasis by inducing lipid droplets in tumor cells and immune exhaustion. Blocking CTLA4 and IL1B significantly suppress tumor progression and metastasis, and the therapeutic efficacy can be further optimized by blocking cyclooxygenases with aspirin.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Sun Young Moon, Minjoo Han, Gyoungah Ryu, Seong-Ah Shin, Jun Hyuck Lee, Chang Sup Lee
Summary: Cancer immunotherapy strategies utilize immune checkpoint inhibitors to induce an antitumor immune response. Recent investigations have highlighted the significance of immune checkpoint molecules in the tumor microenvironment. CD24 and CD200, as immune checkpoint molecules, play important roles in tumor immune evasion, and their therapeutic potential for cancer treatment has been discussed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Yingqi Qiu, Tong Chen, Rong Hu, Ruiyi Zhu, Chujun Li, Yingchen Ruan, Xiaoling Xie, Yuhua Li
Summary: This review highlights the critical role of TAMs in tumor immune evasion, discussing their interactions with other immune cells and factors, and summarizing relevant studies to provide new insights for immunotherapy. Macrophage-targeted therapy is expected to be the next frontier in cancer immunotherapy.
BIOMARKER RESEARCH
(2021)
Article
Immunology
Jin-Qing Liu, Fatemeh Talebian, Lisha Wu, Zhihao Liu, Ming-Song Li, Laichu Wu, Jianmin Zhu, Joseph Markowitz, William E. Carson, Sujit Basu, Xue-Feng Bai
JOURNAL OF IMMUNOLOGY
(2016)
Article
Oncology
Yu Jing, Xiangshu Jin, Lixin Wang, Liping Dou, Quanshun Wang, Yushi Yao, Shimei Lian, Jihao Zhou, Haiyan Zhu, Zilong Yao, Lijun Gao, Lili Wang, Yonghui Li, Xuefeng Bai, Meiyun Fang, Li Yu
Article
Immunology
Zhihao Liu, Lisha Wu, Jing Zhu, Xiaotong Zhu, Jianmin Zhu, Jin-Qing Liu, Jianchao Zhang, Jonathan P. Davis, Sanjay Varikuti, Abhay R. Satoskar, Jie Zhou, Ming-Song Li, Xue-Feng Bai
Article
Oncology
Hua Zhu, Song Gu, Minzhi Yin, Min Shi, Chao Xin, Jianmin Zhu, Jing Wang, Siqi Huang, Chenjie Xie, Jing Ma, Ci Pan, Jingyan Tang, Min Xu, Xue-Feng Bai
PEDIATRIC BLOOD & CANCER
(2018)
Article
Immunology
Jianmin Zhu, Jin-Qing Liu, Zhihao Liu, Lisha Wu, Min Shi, Jianchao Zhang, Jonathan P. Davis, Xue-Feng Bai
FRONTIERS IN IMMUNOLOGY
(2018)
Article
Endocrinology & Metabolism
Hamid Fallah, Arezou Sayad, Fatemeh Ranjbaran, Fatemeh Talebian, Soudeh Ghafouri-Fard, Mohammad Taheri
METABOLIC BRAIN DISEASE
(2020)
Article
Oncology
Cho-Hao Lin, Khadija H. Elkholy, Nissar A. Wani, Ding Li, Peng Hu, Juan M. Barajas, Lianbo Yu, Xiaoli Zhang, Samson T. Jacob, Wasif N. Khan, Xue-Feng Bai, Anne M. Noonan, Kalpana Ghoshal
MOLECULAR CANCER THERAPEUTICS
(2020)
Article
Cell Biology
Aiyan Hu, Miao Ding, Jianmin Zhu, Jin-Qing Liu, Xueliang Pan, Kalpana Ghoshal, Xue-Feng Bai
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2020)
Article
Oncology
Chao Xin, Jianmin Zhu, Song Gu, Minzhi Yin, Jing Ma, Ci Pan, Jingyan Tang, Peng Zhang, Yang Liu, Xue-Feng Bai, Xi Mo, Min Xu, Hua Zhu
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2020)
Article
Oncology
Fouad Choueiry, Molly Torok, Reena Shakya, Kriti Agrawal, Anna Deems, Brooke Benner, Alice Hinton, Jami Shaffer, Bradley W. Blaser, Anne M. Noonan, Terence M. Williams, Mary Dillhoff, Darwin L. Conwell, Phil A. Hart, Zobeida Cruz-Monserrate, Xue-Feng Bai, William E. Carson III, Thomas A. Mace
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Article
Medicine, Research & Experimental
Dan Shu, Long Zhang, Xuefeng Bai, Jianhua Yu, Peixuan Guo
Summary: This study describes the development of a novel Ab-like RNA nanoparticle platform carrying multiple ligands for immunotherapy. Optimized trispecific RNA NPs showed efficient T cell activation, promoted the strongest anti-tumor function of immune cells, and inhibited cancer growth in animal trials. This Ab-like RNA NP platform provides a promising alternative to protein antibodies for tumor immunotherapy.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2021)
Review
Oncology
Jin-Qing Liu, Jianmin Zhu, Aiyan Hu, Alaina Zhang, Chunbaixue Yang, Jianyu Yu, Kalpana Ghoshal, Sujit Basu, Xue-Feng Bai
AMERICAN JOURNAL OF CANCER RESEARCH
(2020)
Article
Biochemistry & Molecular Biology
Jin-Qing Liu, Aiyan Hu, Jianmin Zhu, Jianyu Yu, Fatemeh Talebian, Xue-Feng Bai
TUMOR MICROENVIRONMENT: SIGNALING PATHWAYS, PT A
(2020)
Article
Medicine, Research & Experimental
Jianmin Zhu, Jin-Qing Liu, Min Shi, Xinhua Cheng, Miao Ding, Jianchao C. Zhang, Jonathan P. Davis, Sanjay Varikuti, Abhay R. Satoskar, Lanchun Lu, Xueliang Pan, Pan Zheng, Yang Liu, Xue-Feng Bai